{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:10:23Z","timestamp":1793765423271,"version":"4.6.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute myeloid leukemias (AMLs) have an overall poor prognosis with many high-risk cases co-opting stem cell gene regulatory programs, but the mechanisms through which these programs are propogated remain poorly understood. The increased expression of the stem cell transcription factor, MECOM, underlies a key driver mechanism in largely incurable AMLs. However, how MECOM results in such aggressive AML phenotypes remains unknown. To address existing experimental limitations, we engineered and applied targeted protein degradation with functional genomic readouts to demonstrate that MECOM promotes malignant stem cell\u2013like states by directly repressing prodifferentiation gene regulatory programs. Remarkably and unexpectedly, a single node in this network, a MECOM-bound cis-regulatory element located 42 kilobase (kb) downstream of the myeloid differentiation regulator CEBPA is both necessary and sufficient for maintaining MECOM-driven leukemias. Importantly, the targeted activation of this regulatory element promotes differentiation of these aggressive AMLs and reduces leukemia burden in vivo. These findings suggest a broadly applicable approach for functionally dissecting oncogenic gene regulatory networks to inform improved therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025028954","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:45:19Z","timestamp":1758739519000},"page":"3019-3035","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias"],"prefix":"10.1182","volume":"146","author":[{"given":"Travis J.","family":"Fleming","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Antoszewski","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Lambo","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3654-1741","authenticated-orcid":false,"given":"Michael C.","family":"Gundry","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1859-739X","authenticated-orcid":false,"given":"Riccardo","family":"Piussi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Wahlster","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-328X","authenticated-orcid":false,"given":"Sanjana","family":"Shah","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-7236","authenticated-orcid":false,"given":"Fiona E.","family":"Reed","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2341-8472","authenticated-orcid":false,"given":"Kevin D.","family":"Dong","sequence":"additional","affiliation":[{"name":"5Department of Cell Biology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-413X","authenticated-orcid":false,"given":"Joao A.","family":"Paulo","sequence":"additional","affiliation":[{"name":"5Department of Cell Biology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Gygi","sequence":"additional","affiliation":[{"name":"5Department of Cell Biology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-7684","authenticated-orcid":false,"given":"Claudia","family":"Mimoso","sequence":"additional","affiliation":[{"name":"6Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-3778","authenticated-orcid":false,"given":"Seth R.","family":"Goldman","sequence":"additional","affiliation":[{"name":"6Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Adelman","sequence":"additional","affiliation":[{"name":"6Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Perry","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Stegmaier","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N.","family":"Barrachina","sequence":"additional","affiliation":[{"name":"7Vascular Biology Program, Boston Children\u2019s Hospital, Boston, MA"},{"name":"8Department of Surgery, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-1050","authenticated-orcid":false,"given":"Kellie R.","family":"Machlus","sequence":"additional","affiliation":[{"name":"7Vascular Biology Program, Boston Children\u2019s Hospital, Boston, MA"},{"name":"8Department of Surgery, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3480-6649","authenticated-orcid":false,"given":"Volker","family":"Hovestadt","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Arruda","sequence":"additional","affiliation":[{"name":"9Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-8816","authenticated-orcid":false,"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[{"name":"9Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada"},{"name":"10Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-8641","authenticated-orcid":false,"given":"Richard A.","family":"Voit","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-443X","authenticated-orcid":false,"given":"Vijay G.","family":"Sankaran","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Howard Hughes Medical Institute, Boston, MA"},{"name":"4Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"11Harvard Stem Cell Institute, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025121811215324000_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2025121811215324000_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"issue":"23","key":"2025121811215324000_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2025121811215324000_bib4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jha2.466","article-title":"The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia","volume":"3","author":"Kim","year":"2022","journal-title":"EJHaem"},{"issue":"6","key":"2025121811215324000_bib5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"1","key":"2025121811215324000_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-020-00941-y","article-title":"A single-cell survey of cellular hierarchy in acute myeloid leukemia","volume":"13","author":"Wu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2025121811215324000_bib7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"2025121811215324000_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"7954","key":"2025121811215324000_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"2","key":"2025121811215324000_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"2025121811215324000_bib11","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2011-11-393827","article-title":"EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs","volume":"119","author":"Bindels","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2025121811215324000_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41590-022-01370-4","article-title":"A genetic disorder reveals a hematopoietic stem-cell regulatory network co-opted in leukemia","volume":"24","author":"Voit","year":"2023","journal-title":"Nat Immunol"},{"issue":"12","key":"2025121811215324000_bib13","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/emboj\/19.12.2958","article-title":"The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death","volume":"19","author":"Kurokawa","year":"2000","journal-title":"EMBO J"},{"issue":"1","key":"2025121811215324000_bib14","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1038\/s41467-018-06208-y","article-title":"EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription","volume":"9","author":"Ayoub","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"2025121811215324000_bib15","doi-asserted-by":"crossref","first-page":"e67134","DOI":"10.1371\/journal.pone.0067134","article-title":"Global identification of EVI1 target genes in acute myeloid leukemia","volume":"8","author":"Glass","year":"2013","journal-title":"PLoS One"},{"issue":"31","key":"2025121811215324000_bib16","doi-asserted-by":"crossref","first-page":"E2885","DOI":"10.1073\/pnas.1309310110","article-title":"EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation","volume":"110","author":"Bard-Chapeau","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2025121811215324000_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.2022016592","article-title":"EVI1 drives leukemogenesis through aberrant ERG activation","volume":"141","author":"Schmoellerl","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025121811215324000_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nm.4283","article-title":"The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia","volume":"23","author":"Fenouille","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"2025121811215324000_bib19","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1038\/s41467-024-48953-3","article-title":"Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML","volume":"15","author":"Marchesini","year":"2024","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2025121811215324000_bib20","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1182\/blood-2024-206206","article-title":"Efficacy of combinations of targeted agents against dependencies in mecom rearranged AML identified by unbiased chemical and CRISPR screens","volume":"144","author":"Birdwell","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2025121811215324000_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2025121811215324000_bib22","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1038\/s41467-020-18377-w","article-title":"Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules","volume":"11","author":"Nabet","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"2025121811215324000_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"issue":"4","key":"2025121811215324000_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell"},{"issue":"26","key":"2025121811215324000_bib25","doi-asserted-by":"crossref","first-page":"13591","DOI":"10.1074\/jbc.M115.708156","article-title":"EVI1 interferes with myeloid maturation via transcriptional repression of Cebpa, via binding to two far downstream regulatory elements","volume":"291","author":"Wilson","year":"2016","journal-title":"J Biol Chem"},{"issue":"2","key":"2025121811215324000_bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood.V100.2.701","article-title":"MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors","volume":"100","author":"Masterson","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2025121811215324000_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41594-020-0446-0","article-title":"Enhancer RNAs are an important regulatory layer of the epigenome","volume":"27","author":"Sartorelli","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"7295","key":"2025121811215324000_bib28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature09033","article-title":"Widespread transcription at neuronal activity-regulated enhancers","volume":"465","author":"Kim","year":"2010","journal-title":"Nature"},{"issue":"5","key":"2025121811215324000_bib29","first-page":"2665","article-title":"Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein","volume":"11","author":"Perkins","year":"1991","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2025121811215324000_bib30","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1073\/pnas.1119229109","article-title":"Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors","volume":"109","author":"Bard-Chapeau","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2025121811215324000_bib31","doi-asserted-by":"crossref","first-page":"e1010378","DOI":"10.1371\/journal.pcbi.1010378","article-title":"WhichTF is functionally important in your open chromatin data?","volume":"18","author":"Tanigawa","year":"2022","journal-title":"Plos Comput Biol"},{"issue":"20","key":"2025121811215324000_bib32","doi-asserted-by":"crossref","first-page":"eadk9076","DOI":"10.1126\/sciadv.adk9076","article-title":"Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2","volume":"10","author":"Pastoors","year":"2024","journal-title":"Sci Adv"},{"issue":"28","key":"2025121811215324000_bib33","doi-asserted-by":"crossref","first-page":"25834","DOI":"10.1074\/jbc.M102343200","article-title":"Evi-1 transforming and repressor activities are mediated by CtBP co-repressor proteins","volume":"276","author":"Palmer","year":"2001","journal-title":"J Biol Chem"},{"issue":"10","key":"2025121811215324000_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41419-020-03099-0","article-title":"EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal","volume":"11","author":"Paredes","year":"2020","journal-title":"Cell Death Dis"},{"issue":"7","key":"2025121811215324000_bib35","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2025121811215324000_bib36","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ccell.2023.10.008","article-title":"A longitudinal single-cell atlas of treatment response in pediatric AML","volume":"41","author":"Lambo","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"2025121811215324000_bib37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/leu.2010.47","article-title":"EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia","volume":"24","author":"Balgobind","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2025121811215324000_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.2011.41.5505","article-title":"Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON\/SAKK Cooperative Group","volume":"31","author":"Gr\u00f6schel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025121811215324000_bib39","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2002-05-1459","article-title":"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients","volume":"101","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2003","journal-title":"Blood"},{"issue":"7906","key":"2025121811215324000_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-022-04571-x","article-title":"Mapping human haematopoietic stem-cells from haemogenic endothelium to birth","volume":"604","author":"Calvanese","year":"2022","journal-title":"Nature"},{"issue":"4","key":"2025121811215324000_bib41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nbt.2859","article-title":"The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells","volume":"32","author":"Trapnell","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2025121811215324000_bib42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"8","key":"2025121811215324000_bib43","first-page":"704","article-title":"OCI\/AML-4 an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside","volume":"5","author":"Koistinen","year":"1991","journal-title":"Leukemia"},{"issue":"11","key":"2025121811215324000_bib44","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/nprot.2013.132","article-title":"CRISPR interference (CRISPRi) for sequence-specific control of gene expression","volume":"8","author":"Larson","year":"2013","journal-title":"Nat Protoc"},{"issue":"10","key":"2025121811215324000_bib45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nmeth.2598","article-title":"CRISPR RNA-guided activation of endogenous human genes","volume":"10","author":"Maeder","year":"2013","journal-title":"Nat Methods"},{"issue":"6","key":"2025121811215324000_bib46","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","article-title":"The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins","volume":"94","author":"Pause","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2025121811215324000_bib47","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2016-01-695759","article-title":"An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation","volume":"127","author":"Avellino","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025121811215324000_bib48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nmeth.2847","article-title":"Identification of small molecules that support human leukemia stem-cell activity ex vivo","volume":"11","author":"Pabst","year":"2014","journal-title":"Nat Methods"},{"issue":"2","key":"2025121811215324000_bib49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41375-019-0568-8","article-title":"Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support","volume":"34","author":"Azadniv","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2025121811215324000_bib50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"Kurosaki","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2025121811215324000_bib51","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1038\/s41598-019-45982-7","article-title":"Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells","volume":"9","author":"Huynh","year":"2019","journal-title":"Sci Rep"},{"issue":"21","key":"2025121811215324000_bib52","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1073\/pnas.0502825102","article-title":"Systems analysis of transcriptome and proteome in retinoic acid\/arsenic trioxide-induced cell differentiation\/apoptosis of promyelocytic leukemia","volume":"102","author":"Zheng","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7831","key":"2025121811215324000_bib53","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem-cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"7633","key":"2025121811215324000_bib54","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"issue":"1-2","key":"2025121811215324000_bib55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem-cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J Immunol Methods"},{"issue":"14","key":"2025121811215324000_bib56","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2025121811215324000_bib57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40487-019-0095-9","article-title":"Efficacy of all-trans-retinoic acid in high-risk acute myeloid leukemia with overexpression of EVI1","volume":"7","author":"Paubelle","year":"2019","journal-title":"Oncol Ther"},{"issue":"1","key":"2025121811215324000_bib58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR edits from Sanger trace data","volume":"5","author":"Conant","year":"2022","journal-title":"CRISPR J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/25\/3019\/2476675\/blood_bld-2025-028954-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/25\/3019\/2476675\/blood_bld-2025-028954-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:22:06Z","timestamp":1766074926000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/25\/3019\/547442\/CEBPA-repression-by-MECOM-blocks-differentiation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":58,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025028954","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.30.630680","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,18]]},"published":{"date-parts":[[2025,12,18]]}}}